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LETTER TO THE EDITOR
ANTICARDIOLIPIN ANTIBODIES AND SEVERE LEPTOSPIROSIS
October 15, 2002
Sir,
A recent publication of DAHER et al.2 reports the presence of anticardiolipin antibodies (ACL) in leptospirosis patients and thus confirms another
previous Brazilian study7. Questions regarding the inducing mechanism of ACL and their pathologic significance in acute settings remain open.
In leptospirosis, as in other infections, the trigger of ACL production remains elusive. Are ACL induced by the release of endothelial cryptic
autoantigens, or by cross reactivity, or by an hypothetical leptospire superantigen? Indeed, infections are reported as precipitating conditions of the
catastrophic antiphospholipid syndrome, supposedly by a mechanism of molecular mimicry3. However, studies of Lyme disease, another spirochete
infection, have not provided convincing clues to molecular mimicry: anticardiolipin and anti spirochete antibodies were described as separate
populations5. In human leptospirosis, the induction of ACL by molecular mimicry remains unproved yet and deserves to be addressed by dedicated
studies.
Acute complications of leptospirosis have focused attention, due to their potential lethal outcome and pulmonary hemorrhage outstands among
them. ACL pertain to the definition of the antiphospholipid syndrome and alveolar hemorrhage is an acknowledged complication of this syndrome4.
Then, the implication of ACL in leptospirosis pulmonary bleeding is a tempting hypothesis. In the antiphospholipid syndrome, pulmonary hemorrhage
seems to be related to microvascular thrombosis, with or without capillaritis4. However, comprehensive immunochemical and ultrastructural studies
have been performed in Brazil as well, and such microthromboses were not mentioned6,8. The implication of an immunopathological process in
leptospirosis pulmonary hemorrhage has to be considered: it could provide a rationale to therapeutic options already proposed, such as corticosteroid
boluses1,9. An established proof of such a process would be valuable and awaits additional evidence.
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